3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA

References

• E. de Clercq, Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV, Int. J. Antimicrob. Agents 33 (2009), pp. 307–320.
   PubMed Web of Science ®Google Scholar
• M. Radi, G. Maga, M. Alongi, L. Angeli, A. Samuele, S. Zanoli, L. Bellucci, A. Tafi, G. Casaluce, G. Giorgi, M. Armand-Ugon, E. Gonzalez, J.A. Este, M. Baltzinger, G. Bec, P. Dumas, E. Ennifar, and M. Botta, Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants, J. Med. Chem. 52 (2009), pp. 840–851.
   PubMed Web of Science ®Google Scholar
• E. de Clercq, Antiretroviral drugs, Curr. Opin. Pharmacol. 10 (2010), pp. 507–515.
   PubMed Web of Science ®Google Scholar
• M.P. De Bethune, Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009), Antiviral Res. 85 (2010), pp. 75–90.
   PubMed Web of Science ®Google Scholar
• E. de Clercq, In search of a selective therapy of viral infections, Antiviral Res. 85 (2010), pp. 19–24.
   PubMed Web of Science ®Google Scholar
• D. Jochmans, Novel HIV-1 reverse transcriptase inhibitors, Virus Res. 134 (2008), pp. 171–185.
   PubMed Web of Science ®Google Scholar
• C. Mugnaini, M. Alongi, A. Togninelli, H. Gevariya, A. Brizzi, F. Manetti, C. Bernardini, L. Angeli, A. Tafi, L. Bellucci, F. Corelli, S. Massa, G. Maga, A. Samuele, M. Facchini, I. Clotet-Codina, M. Armand-Ugon, J.A. Este, and M. Botta, Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: Synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants, J. Med. Chem. 50 (2007), pp. 6580–6595.
   PubMed Web of Science ®Google Scholar
• A. Mai, M. Artico, G. Sbardella, S. Quartarone, S. Massa, A.G. Loi, A. De Montis, F. Scintu, M. Putzolu, and P. La Colla, Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series, J. Med. Chem. 40 (1997), pp. 1447–1454.
   PubMed Web of Science ®Google Scholar
• O.J. D’Cruz and F.M. Uckun, Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase, J. Enzyme Inhib. Med. Chem. 21 (2006), pp. 329–350.
   PubMed Web of Science ®Google Scholar
• A. Mai, M. Artico, G. Sbardella, S. Massa, E. Novellino, G. Greco, A.G. Loi, E. Tramontano, M.E. Marongiu, and P. La Colla, 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: Novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives, J. Med. Chem. 42 (1999), pp. 619–627.
   PubMed Web of Science ®Google Scholar
• M.B. Nawrozkij, D. Rotili, D. Tarantino, G. Botta, A.S. Eremiychuk, I. Musmuca, R. Ragno, A. Samuele, S. Zanoli, M. Armand-Ugon, I. Clotet-Codina, I.A. Novakov, B.S. Orlinson, G. Maga, J.A. Este, M. Artico, and A. Mai, 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile, J. Med. Chem. 51 (2008), pp. 4641–4652.
   PubMed Web of Science ®Google Scholar
• A. Mai, M. Artico, D. Rotili, D. Tarantino, I. Clotet-Codina, M. Armand-Ugon, R. Ragno, S. Simeoni, G. Sbardella, M.B. Nawrozkij, A. Samuele, G. Maga, and J.A. Este, Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains, J. Med. Chem. 50 (2007), pp. 5412–5424.
   PubMed Web of Science ®Google Scholar
• H. Qin, C. Liu, Y. Guo, R. Wang, J. Zhang, L. Ma, Z. Zhang, X. Wang, Y. Cui, and J. Liu, Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors, Bioorg. Med. Chem. 18 (2010), pp. 3231–3237.
   PubMed Web of Science ®Google Scholar
• Y. Wang, F.E. Chen, J. Balzarini, E. de Clercq, and C. Pannecouque, Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues, Chem. Biodivers. 5 (2008), pp. 168–176.
   PubMed Web of Science ®Google Scholar
• M. Yu, X. Liu, Z. Li, S. Liu, C. Pannecouque, and E. de Clercq, Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonylmethylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs, Bioorg. Med. Chem. 17 (2009), pp. 7749–7754.
   PubMed Web of Science ®Google Scholar
• J. Zhang, P. Zhan, J. Wu, Z. Li, Y. Jiang, W. Ge, C. Pannecouque, E. de Clercq, and X. Liu, Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors, Bioorg. Med. Chem. 19 (2011), pp. 4366–4376.
   PubMed Web of Science ®Google Scholar
• M. Yu, Z. Li, S. Liu, E. Fan, C. Pannecouque, E. de Clercq, and X. Liu, Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs, ChemMedChem 6 (2011), pp. 826–833.
   PubMed Web of Science ®Google Scholar
• S. Wold, Cross validatory estimation of the number of components in factor and principal component analysis, Technometrics 20 (1978), pp. 397–406.
   Web of Science ®Google Scholar
• M.S. Castilho, M.P. Postigo, C.B. de Paula, C.A. Montanari, G. Oliva, and A.D. Andricopulo, Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors, Bioorg. Med. Chem. 14 (2006), pp. 516–527.
   PubMed Web of Science ®Google Scholar
• B. Salum Lde, I. Polikarpov, and A.D. Andricopulo, Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies, J. Mol. Graph. Model. 26 (2007), pp. 434–442.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer and M. Amanlou, 3D-QSAR analysis of anti-cancer agents by CoMFA and CoMSIA, Med. Chem. Res. 23 (2013), pp. 800–809.
   Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967.
   PubMed Web of Science ®Google Scholar
• G. Klebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130–4146.
   PubMed Web of Science ®Google Scholar
• J.L. Melville and J.D. Hirst, On the stability of CoMFA models, J. Chem. Inf. Comput. Sci. 44 (2004), pp. 1294–1300.
   PubMedGoogle Scholar
• A. Golbraikh, M. Shen, Z. Xiao, Y.D. Xiao, K.H. Lee, and A. Tropsha, Rational selection of training and test sets for the development of validated QSAR models, J. Comput. Aided Mol. Des. 17 (2003), pp. 241–253.
   PubMed Web of Science ®Google Scholar
• W. Li, B. Huang, D. Kang, E. de Clercq, D. Daelemans, C. Pannecouque, P. Zhan, and X. Liu, Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors, Chem. Biol. Drug. Des. 88 (2016), pp. 380–385.
   PubMed Web of Science ®Google Scholar